Latest Agomab Therapeutics News & Updates

See the latest news and media coverage for Agomab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Agomab Therapeutics (Agomab)

Clinical-stage biopharmaceutical company developing fibrosis therapies

agomab.com

Headquarters: Antwerp, Belgium
Founded year: 2017
Company type: Private company
Number of employees: 70–200

Last updated Today

Latest news about Agomab Therapeutics (Agomab)

In short: Agomab Therapeutics transitioned to a public company via a $208 million Nasdaq IPO and advanced its fibrosis pipeline into multiple Phase 2 trials.

Company announcements

Yesterday Agomab

Agomab announces design of NOV-ERA Phase 2b study for ontunisertib

The study targets fibrostenosing Crohn's disease with a novel primary endpoint of endoscopic passability, with dosing expected in H2 2026.

April 23 Agomab

Agomab reports full year 2025 financial results

It raised $208M in Feb 2026, held €116.5M year-end cash, expects runway into H1 2029, and plans Phase 2 starts with topline readouts in H2 2026.

March 26 Agomab

Agomab receives U.S. patent for AGMB-447

The patent covers the inhaled ALK5 inhibitor in Phase 1b for IPF, providing IP protection through 2041. CEO highlights it as a key milestone.

March 10 Agomab

Agomab Therapeutics presents positive Phase 2a results

Nature Reviews highlights their ontunisertib presentation for Fibrostenosing Crohn’s disease at ECCO'26 Congress.

Media coverage

June 4 Investing.com

Agomab prices IPO at $16 per share, aims to raise $200 million

Agomab Therapeutics NV (AGMB) priced its initial public offering at $16.00 per American Depositary Share, the Belgium-based biopharmaceutical company announced February 5.

April 23 Markets Insider

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO...

April 12 Yahoo Finance

AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447

Learn more AgomAb Therapeutics NV (NASDAQ:AGMB) is one of the 7 Best Strong Buy European Stocks to Invest In. On March 26, 2026, AgomAb Therapeutics...

March 31 American Banking News

Analyzing AgomAb Therapeutics (NASDAQ:AGMB) & Prime Medicine (NASDAQ:PRME) - American Market News

AgomAb Therapeutics (NASDAQ:AGMB – Get Free Report) and Prime Medicine (NASDAQ:PRME – Get Free Report) are both small-cap manufacturing companies, but which is the better...

Never miss news about Agomab

Track Agomab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Agomab competitors & trending companies

Browse news for competitors to Agomab and other trending companies.